The GSC's faculty members apply their expertise in genomics, bioinformatics, proteomics, precision medicine, computational biology and software development to advance knowledge of cancer and other diseases, operating as one of nine departments of BC Cancer Research. 

Personalized OncoGenomics (POG)

The BC Cancer Personalized OncoGenomics (POG) Program is a clinical research initiative consisting of oncologists, pathologists and other clinical, research and technical personnel, that aims to study the impact of embedding genomic sequencing into real-time treatment planning for B.C. patients with otherwise incurable metastatic cancers.

POGA key research objective for the POG program is to identify and better understand the genomic alterations that drive cancer and its progression and metastasis. The program is providing data-driven genomic explanations for treatment failure, helping to determine which treatments are likely to be ineffective and is identifying potential therapeutic targets for individual cancer patients.

Read more.

Software Development

The rapid evolution of DNA sequencing technologies has made it possible to generate enormous amounts of data, and has subsequently spurred the development of computational tools needed to assemble complete genomes and to analyze genomic, transcriptomic and proteomic data.

The GSC collaborates with and supports research by the wider research community. We have an extensive collection of software packages developed in-house available for download.

Visit our Software Centre to learn more.

The Healthy Aging Study

The Healthy Aging Study is a collaboration between the Genome Sciences Centre and other leading research groups investigating the individual factors which contribute to healthy aging and resistance to age-related disease. 

Read More.

Colorectal Cancer Screening

Colorectal cancer is the second leading cause of cancer-related death in Canada. The goal of this program is to develop novel easy-to-administer tests that identify individuals at the earliest, most curable stages of the disease.

Read More.


The study of autophagy in human health is a new research field that has recently generated tremendous attention due to the recognition that autophagy is involved in multiple developmental processes and various human diseases including cancer. 

Read More.

Antimicrobial Peptide Discovery

A collaborative project in Dr. Birol’s group is focusing on short proteins called antimicrobial peptides (AMPs), which are produced naturally by various animal and plant species.

Read More.

Cancer Bioinformatics

We aim to use bioinformatics to investigate the landscape of mutations present in cancer genomes and the early genomic events that give rise to and promote the progression of cancer. 

Read More.

Cancer Epigenetics

We are working to understand the role of epigenetics in cancer and to investigate the therapeutic potential of interventions directed at epigenetic processes. 

Read More.

Aberrant RNA Processing in Cancer

A major research focus is the regulatory mechanisms of aberrant RNA processing in cancer, particularly the regulation of alternative pre-mRNA splicing and processing, and miRNA biogenesis. 

Read More.

Lymphoid Cancer Family Studies

We have undertaken a family-based study to identify genetic factors contributing to lymphoid cancers including lymphoma, leukemia and myeloma. 

Read More.

Cancer Genomes and Epigenomes

The interplay between the genome and the epigenome is exploited by cancer cells. We are analyzing the cancer regulatory networks with the goal to understand the consequence of epigenomic dysregulation.

Read More. 


Cancer immunotherapies using engineered autologous T cells have shown remarkable efficacy against some cancer. Dr. Holt’s team is engineering T cells to selectively deliver modified cytotoxic payloads and pro-drug activators for the purpose of enhanced tumour cell killing and overcoming immune resistance.

Read More.

Cancer and Infectious Agents

A substantial proportion (at least 15 per cent) of the global cancer burden is attributable to known infectious agents. The Holt Lab finds pathogens by their sequence signatures in human tissues using genomic methods, which revealed a strong link between colorectal carcinoma and Fusobacterium nucleatum.

Read More.

Cancer Drug Resistance

The aim of this project is to understand the mechanisms of Lenalidomide resistance in Myelodysplastic Syndromes (MDS), as well as to potentially provide strategies to overcome or bypass resistance.

Read More.

Burkitt Lymphoma

This project seeks to generate high-throughput whole genome and transcriptome sequencing data from over 100 Burkitt lymphoma tumours in order to elucidate the genetic and molecular underpinnings of the disease.

Read More.

Non-coding Mutations in NHLs

We are seeking to identify driver mutations that contribute to some features of Non Hodgkin Lymphomas using data-driven comprehensive methods that allow identification of non-coding mutations relevant to malignancy.

Read More.

Novel Prostate Cancer Therapies

The Sadar lab has identified the N-terminal domain of the androgen receptor as a novel therapeutic target for the development of novel prostate cancer therapeutics. 

Read More. 

Back to top